Mithra Pharmaceuticals - Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator)
12 mai 2023 11h45 HE
|
Mithra Pharmaceuticals
Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator) Liege, Belgium, 12 May 2023 – 17:50 CET – Mithra Pharmaceuticals SA...
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients
11 mai 2023 01h30 HE
|
Mithra Pharmaceuticals
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients Trial designed to address limited clinical data in this population despite widespread use of Combined...
Mithra and the University of Liège Secure Proof-of-Concept for Novel Manufacturing Process of Estetrol
04 mai 2023 01h30 HE
|
Mithra Pharmaceuticals
Collaboration demonstrates Mithra’s commitment to innovation and sustainable drug supply in Women’s Health Liege, Belgium, 04 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company...
Publication of a transparency notification received from Alychlo NV
28 avr. 2023 11h45 HE
|
Mithra Pharmaceuticals
Liege, Belgium, 28 April 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007...
Mithra annonce ses résultats annuels 2018
01 mars 2019 07h00 HE
|
Mithra Pharmaceuticals
Mithra annonce ses résultats annuels 2018 Forte croissance du chiffre d'affaires (+42%) et amélioration significative de l'EBITDA qui atteint un niveau record (38,3 millions EUR contre -18,4...
Mithra Reports 2018 Annual Results
01 mars 2019 07h00 HE
|
Mithra Pharmaceuticals
Mithra Reports 2018 Annual Results Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M...
Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada
30 janv. 2019 07h00 HE
|
Mithra Pharmaceuticals
Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada Primary efficacy endpoint indicates excellent contraceptive efficacy, with a Pearl Index...